Prof. Anat Lowenstein of Tel Aviv University, Israel, discusses the innovative moves towards incorporating head-wearable devices in surgical theatres and the importance of improving outcomes in the management of AMD patients with home monitoring, a field particularly noteworthy during the COVID-19 pandemic.
Dr Tunde Peto explains that the rate of blindness from diabetes continues to increase by 8% annually and the only way to prevent this may well rest with well-planned, evidence-based services.
A port delivery system with ranibizumab with dosing every 24 weeks has been shown in a Phase III trial to be equivalent to monthly intravitreal ranibizumab injection to treat neovascular age-related macular degeneration, according to Dr Carl Regillo, who reported on behalf of the Archway Trial investigators.
Mehran Nouroozian, Regional Manager at Oertli for the Middle East Region, India, and Turkey at Oertli, shows off the company’s newest product additions during this year's virtual meeting.
Prof. Frank Holz, Chairman of the Department of Ophthalmology at the University of Bonn, Germany, highlights the topics, lectures, symposia and instructional courses that will take place at this year’s virtual EURETINA conference, and gives his insights on the hot topics of the dynamic retina field.
Heads-up surgery is moving into the next generation of vitreoretinal surgery, with novel technologies being developed for surgeons.
The first reported clinical results of a Phase I study following implantation of the 3-D neural interface retinal prosthesis showed it is safe in patients with end-stage retinitis pigmentosa.
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.
Modifier-25 same-day examinations are critical to the successful treatment and overall health and well being of these patients.
Measuring high-quality care cannot be a barrier to providing it, notes John T. Thompson, MD.
Results could provide a new preferred treatment paradigm for this population
Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.
Researchers advocate for intraoperative intravitreal steroid during cataract surgery in patients with DME.
A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.
Study explores correlations between functional and structural tests
S.K. Steven Houston III, MD, shares how his practice has put to use recent retina innovations and adapted to accommodate the ever-changing operating room spacing and set-up in the current COVID-19 environment.
The application of sub-silicone oil TA crystals over relaxing retinectomy sites is a viable option in patients with complex RD with extreme PVR.
Retina specialists Caesar Luo, MD, of Bay Area Retina Associates, and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.
Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."
S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment
Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.
Investigators tested the hypothesis that changes in certain areas of the macular are more relevant to AMD. What did their findings reveal?
Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.
Rates of anxiety and depression increased but were not necessarily tied to disease severity
A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?
Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
